The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis (Q38537377)

3 September 2017

0 references

1 reference

title

The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis (English)

1 reference

3 September 2017

1 reference

1 reference

3

0 references

author name string

Emma O Billington

series ordinal

1

1 reference

PubMed ID

26109213

3 September 2017

Andrew Grey

series ordinal

2

1 reference

3 September 2017

25 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

58

1 reference

3 September 2017

2238-2246

1 reference

3 September 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-015-3660-2

3 September 2017

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

A cohort study of thiazolidinediones and fractures in older adults with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

The risk of fractures associated with thiazolidinediones: a self-controlled case-series study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Skeletal consequences of thiazolidinedione therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve ty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Imputation methods for missing outcome data in meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Thiazolidinedione use and bone loss in older diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Intensive glycemic control and thiazolidinedione use: effects on cortical and trabecular bone at the radius and tibia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Skeletal health in adults with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

PPAR-gamma regulates osteoclastogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Osteoblast physiology in normal and pathological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

The DREAM trial – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-015-3660-2

Biochemical markers as predictors of rates of bone loss after menopause

21 January 2018

1 reference

12 December 2020

Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus

1 reference

12 December 2020

Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens

1 reference

12 December 2020

Risk of fracture with thiazolidinediones: an individual patient data meta-analysis.

1 reference

12 December 2020

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

12 December 2020

Rosiglitazone decreases bone mass and bone marrow fat

1 reference

12 December 2020

Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women

1 reference

12 December 2020

A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone.

1 reference

12 December 2020

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus

1 reference

12 December 2020

10.1007/S00125-015-3660-2

Identifiers

DOI

1 reference

PubMed ID

26109213

Dimensions Publication ID

3 September 2017

0 references

1 reference

PubMed ID

26109213